<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/702F75F0-D470-4EBF-B8D1-61F5EACD8168"><gtr:id>702F75F0-D470-4EBF-B8D1-61F5EACD8168</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>M</gtr:otherNames><gtr:surname>Elliott</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0800161"><gtr:id>CE801478-31BA-4DD9-A8EE-030777542F86</gtr:id><gtr:title>Hantavirus reverse genetics and innate immune responses</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0800161</gtr:grantReference><gtr:abstractText>Hantaviruses are a group of viruses that cause lifelong infections mice, rats and other rodents without causing disease. However, if humans become infected by inhaling infected-rodent urine contaminated dust, they can become very ill with severe diseases called haemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Death rates can be as high as 35%. We want to understand details of how hantaviruses grow at the molecular level and how they deal with the cell?s defence mechanisms. To aid these studies we will develop methodology to apply recombinant DNA techniques to make viruses containing defined genetic changes in their genomes that are debilitated in their growth properties and could be used as potential vaccines. In addition, our studies will provide important new information that may help in the design of new antiviral drugs.</gtr:abstractText><gtr:technicalSummary>Hantaviruses comprise one genus within the family Bunyaviridae and include some of the most important human pathogens in that family, including those causing haemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome. Hantaviruses have a worldwide distribution and are recognised as posing an increasing threat to human helath. Despite the significant medical impact of hantaviruses, many aspects of their replication and interaction with host cells are incompletely understood. A major impediment to the study of hantaviruses is the lack of a reverse genetics system. In addition, hantaviruses grow less well in tissue culture compared to, for example, orthobunyaviruses, presenting technical difficulties. Thus, in this project we will (a) investigate cell lines that should allow improved growth of hantaviruses; (b) develop reverse genetics systems for hantaviruses; (c) investigate aspects of hantavirus RNA synthesis; (d) attenuate hantavirus replication in cell culture via reverse genetics; and (e) investigate the interactions of strongly pathogenic, weakly pathogenic and apathogenic hantaviruses with host innate immune systems. These studies will lead to an increased understanding of hantavirus replication and lay the foundation for future work to develop novel hantaviruses as potential vaccines.</gtr:technicalSummary><gtr:fund><gtr:end>2014-03-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1406893</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>306892</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Project Grant</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>Biotechnology and Biological Sciences Research Council (BBSRC)</gtr:fundingOrg><gtr:id>520CB127-9C77-472F-9CA5-7B7B3E3B5C19</gtr:id><gtr:outcomeId>qSkEhg4hXEZ0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2659281</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Senior Investigator Award</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>099220</gtr:fundingRef><gtr:id>E178E6C3-0AF9-4065-95D5-3DE7A5701A12</gtr:id><gtr:outcomeId>ZgKUdpbU5eM</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>501200</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Equipment Grant</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>64483586-0F65-41FD-8652-AA6236EC8786</gtr:id><gtr:outcomeId>ZQLSKMzpbki0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1503942</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Programme Grant</gtr:description><gtr:end>2012-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>FBF2A88A-7584-4107-AC0C-34B8080BF4B1</gtr:id><gtr:outcomeId>PmkaV8kR93m0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2006-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>various mammalian cell lines that constitutively express bacteriophage T7 RNA polymerase</gtr:description><gtr:id>415D51B2-4A17-436E-951A-D68E3CCCEE57</gtr:id><gtr:impact>cell lines that are starting point for development of hantavirus reverse genetics</gtr:impact><gtr:outcomeId>szyMRqwRFaZ</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>T7 polymerase cell lines</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2010</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>polyclonal rabbit antibody to bacterially-expressed Puumala virus nucleocapsid protein; cross reactive with N proteins of various hantaviruses</gtr:description><gtr:id>C2A749A9-1A53-4BC9-81DC-AF6C90F288D0</gtr:id><gtr:impact>enabled better infectivity assay for hantaviruses</gtr:impact><gtr:outcomeId>qii87BwEPmn</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>hantavirus N protein AB</gtr:title><gtr:type>Antibody</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Determination of complete genome sequence of cell-culture adapted Puumala hanatvirus and generation of cDNA clones containing the correct sequences.</gtr:description><gtr:id>F5082017-D4E2-4586-85D9-864284400364</gtr:id><gtr:impact>Obtaining the exact nucleotide sequence and correct cDNA clones is essential to the goal of reverse genetics. We will correct database entries once we have proven functionality of the clones.</gtr:impact><gtr:outcomeId>L46Buw1irUU</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>cDNA clones of Puumala virus</gtr:title><gtr:type>Database/Collection of Data/Biological Samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>use of new overlay medium for hantavirus infectious centre assay</gtr:description><gtr:id>09FA12D4-188D-4060-AB5A-149B8107815A</gtr:id><gtr:impact>more convenient and sensitive infectivity assay has been developed</gtr:impact><gtr:outcomeId>ofiipDHMxJ9</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>infectious centre assay</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>881C5798-3DEA-49BE-974B-F293892424CD</gtr:id><gtr:title>Attenuation of bunyamwera orthobunyavirus replication by targeted mutagenesis of genomic untranslated regions and creation of viable viruses with minimal genome segments.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fc9fb19d3636f659c800b62dfabb8749"><gtr:id>fc9fb19d3636f659c800b62dfabb8749</gtr:id><gtr:otherNames>Mazel-Sanchez B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_16089_29_23035233</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>80CB5F02-BB0F-4EE4-86AF-1B6E35D5622B</gtr:id><gtr:title>Creation of a recombinant Rift Valley fever virus with a two-segmented genome.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/349eca192dba841263a7ce9b6925cd59"><gtr:id>349eca192dba841263a7ce9b6925cd59</gtr:id><gtr:otherNames>Brennan B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_16089_29_21795328</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F4577F8F-017F-454C-99D4-0A5DAC479585</gtr:id><gtr:title>Establishment of a reverse genetics system for Schmallenberg virus, a newly emerged orthobunyavirus in Europe.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/921e4192888fe4f2765c8e5e7dfad1de"><gtr:id>921e4192888fe4f2765c8e5e7dfad1de</gtr:id><gtr:otherNames>Elliott RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>545b5f79141245.49340282</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>549E0290-2912-40C1-961E-EE47443727B3</gtr:id><gtr:title>Visualizing the replication cycle of bunyamwera orthobunyavirus expressing fluorescent protein-tagged Gc glycoprotein.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1f7a44e64e5dc4d5bc53241fcacefa95"><gtr:id>1f7a44e64e5dc4d5bc53241fcacefa95</gtr:id><gtr:otherNames>Shi X</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_16089_29_20573824</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>60CF90DF-8FEB-4020-AA3A-F245DFD70760</gtr:id><gtr:title>The consequences of reconfiguring the ambisense S genome segment of Rift Valley fever virus on viral replication in mammalian and mosquito cells and for genome packaging.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/349eca192dba841263a7ce9b6925cd59"><gtr:id>349eca192dba841263a7ce9b6925cd59</gtr:id><gtr:otherNames>Brennan B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn><gtr:outcomeId>545b5f78e2ad70.45778474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3678A16F-2A21-4249-A602-AC34DEB41013</gtr:id><gtr:title>The small genome segment of Bunyamwera orthobunyavirus harbours a single transcription-termination signal.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a76013133d37a9be1dcd6b9335fbe53"><gtr:id>2a76013133d37a9be1dcd6b9335fbe53</gtr:id><gtr:otherNames>Blakqori G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_16089_29_22513389</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A565437F-1888-43E1-9715-F1D0B0FDC1F7</gtr:id><gtr:title>Viperin, MTAP44, and protein kinase R contribute to the interferon-induced inhibition of Bunyamwera Orthobunyavirus replication.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/855357de3b138db9d9a9801a9eacc9b5"><gtr:id>855357de3b138db9d9a9801a9eacc9b5</gtr:id><gtr:otherNames>Carlton-Smith C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>pm_16089_29_22896602</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DD5966A-7E2E-4E1D-ABAE-4506D258FC26</gtr:id><gtr:title>Emerging phleboviruses.</gtr:title><gtr:parentPublicationTitle>Current opinion in virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/921e4192888fe4f2765c8e5e7dfad1de"><gtr:id>921e4192888fe4f2765c8e5e7dfad1de</gtr:id><gtr:otherNames>Elliott RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1879-6257</gtr:issn><gtr:outcomeId>545b5f78bb96e6.20679445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79B24712-536F-45F0-A705-D3E2FB75958B</gtr:id><gtr:title>The N-terminus of Bunyamwera orthobunyavirus NSs protein is essential for interferon antagonism.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5c8b4760991ae246242c7b4de560d53c"><gtr:id>5c8b4760991ae246242c7b4de560d53c</gtr:id><gtr:otherNames>van Knippenberg I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>pm_16089_29_20427562</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C041B7C-4AB2-4039-A9A4-5CF90175BB44</gtr:id><gtr:title>Generation and characterization of a recombinant Rift Valley fever virus expressing a V5 epitope-tagged RNA-dependent RNA polymerase.</gtr:title><gtr:parentPublicationTitle>The Journal of general virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/349eca192dba841263a7ce9b6925cd59"><gtr:id>349eca192dba841263a7ce9b6925cd59</gtr:id><gtr:otherNames>Brennan B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1317</gtr:issn><gtr:outcomeId>doi_55f94b94b7a62cc1</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0800161</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>